|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Anti-Cancer(Oncology) Agents
|
Panobinostat(LBH-589)
| Catalogue No. : |
C13981 |
| Product Name: |
Panobinostat(LBH-589) |
| Synonym: |
LBH589;Panobinostat;LBH-589;NVP-LBH-589 |
| Chemical Name: |
N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]phenyl]-2(E)-propenamide |
| CAS No. : |
404950-80-7 |
| Structure : |
|
| Molecular Formula: |
C21H23N3O2 |
| Molecular Weight: |
349.43 |
| Purity: |
>98% |
| Usage: |
Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
